New Omada Health Analysis Shows Long-Term Weight Maintenance Post-GLP-1 Discontinuation, Challenging Industry Assumptions

Core Insights - Omada Health's analysis indicates that 63% of members maintained or continued to lose weight one year after discontinuing GLP-1 medications, challenging the assumption of inevitable weight regain post-medication [1][2][3] - The average weight change among members was only 0.8% after one year, significantly lower than the typical 11-12% weight gain observed in clinical trials without lifestyle support [2][4] Group 1: Analysis Findings - The retrospective analysis involved 816 members and tracked weight change at 6, 9, and 12 months post-GLP-1 discontinuation, showing consistent weight maintenance with minimal average changes of 0.03% at 6 months and 0.6% at 9 months [2][4] - Omada's program emphasizes the importance of lifestyle support, including behavioral guidance and connected devices, to help members maintain weight loss after stopping GLP-1s [3][4] Group 2: Implications for Employers - The findings suggest that Omada's program can help employers manage rising costs associated with GLP-1 medications by preventing wasted healthcare dollars and ensuring effective weight maintenance [3][4] - Omada Health's approach aims to deliver lasting value to both members and customers by supporting weight loss and maintenance throughout the GLP-1 journey [3][4] Group 3: Company Overview - Omada Health is a virtual-first healthcare provider focused on improving health outcomes and containing healthcare costs, with over a decade of experience and more than 30 peer-reviewed publications [5][6] - The company serves over 2,000 customers, including health plans, health systems, and employers, ranging from small businesses to Fortune 500 companies [5][6]